|
Market Closed -
Nasdaq
00:00:00 12/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 9.850 USD | -0.66% |
|
-0.51% | +60.16% |
| 08-14 | ImmuCell Corporation, Q2 2026 Earnings Call, Aug 14, 2026 | |
| 08-14 | ImmuCell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Business description: ImmuCell Corporation

Number of employees: 73
Sales by Activity: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Scours | - | 18.41M | 17.29M | 26.31M | 27.45M |
Mastitis | - | 155K | 178K | 179K | 196K |
Biotechnology | 19.24M | - | - | - | - |
Other | - | 1.46K | - | - | - |
Geographical breakdown of sales: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 16.62M | 17.02M | 15.95M | 22.89M | 24.39M |
Other | 2.62M | 1.55M | 1.52M | 3.6M | 3.25M |
Executive Committee: ImmuCell Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 01/11/2025 | |
Timothy Fiori
DFI | Director of Finance/CFO | 47 | 07/04/2025 |
| Comptroller/Controller/Auditor | - | - |
Composition of the Board of Directors: ImmuCell Corporation
| Director | Title | Age | Since |
|---|---|---|---|
David Tomsche
CHM | Chairman | 69 | 01/12/2013 |
Paul Wainman
BRD | Director/Board Member | 61 | 31/03/2014 |
Gloria Basse
BRD | Director/Board Member | 66 | 10/06/2020 |
| Director/Board Member | 54 | 01/11/2025 | |
Kathy Turner
BRD | Director/Board Member | 62 | 01/04/2026 |
| Director/Board Member | 64 | 15/04/2026 | |
Anthony DiMarco
BRD | Director/Board Member | 63 | 15/04/2026 |
Company details: ImmuCell Corporation

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.66% | -0.51% | +66.39% | +103.09% | 89.46M | ||
| -0.65% | -2.93% | +47.70% | +86.17% | 994B | ||
| -0.29% | -3.51% | +49.15% | +62.35% | 640B | ||
| +0.83% | +0.26% | +17.76% | +72.25% | 454B | ||
| -0.38% | -3.59% | +30.13% | +35.17% | 337B | ||
| -0.09% | -13.54% | +13.34% | +24.95% | 261B | ||
| -0.43% | -2.48% | -0.73% | +9.58% | 246B | ||
| -1.34% | -13.70% | +36.53% | +44.96% | 204B | ||
| -3.44% | -7.51% | -20.63% | -59.44% | 190B | ||
| -0.75% | -4.82% | +25.46% | +87.14% | 178B | ||
| Average | -0.72% | -5.23% | +26.51% | +46.62% | 350.49B | |
| Weighted average by Cap. | -0.51% | -4.42% | +30.96% | +54.95% |
- Stock Market
- Stocks
- ICCC Stock
- Company ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions

















